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ABSTRACT
Introduction: Breast cancer is a multifactorial disease as a result of interaction between ge-
netic and environmental factors such as hormonal, infection, chemical material, and radiation.
Until now, it took as the most occurred of cancer in women, which have the highest mortality in
the world. However, its cause still unknown. According to epidemiologic and clinical and labo-
ratory studies, it was found that there are many risk factors which have important roles in
female breast cancer like menarche, menopause, endogenous and exogenous hormones,
family history (genetics), parity, lactation, obesity, physical activity, diet, alcohol, smoking, en-
vironmental factors and history of biopsy and breast examination. The aims of this study to
evaluate and compare the clinicopathological features in the four breast cancer subtypes de-
fined by immunohistochemistry expression of ER, PR, and HER-2: ER/PR+, HER-2+ (Luminal
B); ER/PR+,HER-2- (Luminal A); ER/PR-, HER-2+ (HER-2 type) and ER-/PR-, HER-2- (Triple
negative) type. Methods: This study was a retrospective study of 89 invasive breast cancer.
Clinical and pathologic features of the four subtypes were compared. ER/PR+, HER2+; ER/
PR+, HER2-; ER/PR-, HER2+; and ER/PR-,HER2- types were  10 (11.2%), 35 (39.3%), 27
(30.3%), and 17 (19.1%) samples. Results: Subjects with ER/PR-, HER2- where are likely to
be younger (p<0.001). In tumor subtypes with HER2+, the number of subjects with poorly
differentiated was larger than the total number of well and moderate differentiated (p < 0.001).
There was no significant difference of metastatic to lymph node status in all subtypes. Conclu-
sion: Subtype luminal A of breast cancer have a high number than other subtypes. There was
a correlation between overexpression of HER-2 with poorly differentiated of breast cancer but
not with a metastatic capability of tumor cells to lymph nodes.
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INTRODUCTION
Breast epithelial neoplasms are the most
frequently diagnosed neoplasm in women and
more than 95% of breast cancer originate from
epithelial, which is namely adenocarcinoma.
Based on data from Globocan 2012, the
breast cancer incidence ranks in second place
and is the most common cancer in women in
developing countries and developed countries
with 1.67 million new cases (25% of all can-
cers) per year. Breast cancer is also the most
common cause of death in women in devel-
oping countries (14.3% of total mortality due
to cancer). In Indonesia, Globocan data from
2012 showed the incidence of breast cancer
is 16.4% of all cancers with a mortality of
10.2% of total cancer mortality. Breast can-
cer is still the most common malignancy and
the leading cause of death in women in Indo-
nesia.1
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